{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01228266",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CMM-EM"
      },
      "Organization": {
        "OrgFullName": "Hospital Clinic of Barcelona",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cell Transplantation in MS",
      "OfficialTitle": "Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study",
      "Acronym": "CMM-EM"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2014",
      "OverallStatus": "Terminated",
      "WhyStopped": "Ended the recruitment in June 2012 for low enrollement accrual",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 2010"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2013",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2013",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "October 25, 2010",
      "StudyFirstSubmitQCDate": "October 25, 2010",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 26, 2010",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "February 12, 2014",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 13, 2014",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Albert Saiz",
        "ResponsiblePartyInvestigatorTitle": "MD",
        "ResponsiblePartyInvestigatorAffiliation": "Hospital Clinic of Barcelona"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Albert Saiz",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Instituto de Salud Carlos III",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The study is a randomized Phase II study, masked and crossed-over with placebo to evaluate the safety and tolerability of autologous mesenchymal stem cell transplantation in patients with active multiple sclerosis"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Multiple Sclerosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Multiple Sclerosis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Crossover Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "9",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "autologous mesenchymal stem cell",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: autologous mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "autologous mesenchymal stem cells",
            "InterventionDescription": "A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "autologous mesenchymal stem cell"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "To evaluate the safety as number of severe events along 1 year, and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI at 6 months and at the end of the study",
            "PrimaryOutcomeDescription": "The coprimary endpoints were safety and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "To evaluate effects on MS disease activity measured by: clinical variables, MRI, OCT, immunological analysis and quality of life scales",
            "SecondaryOutcomeDescription": "clinical outcomes (number of relapses and change in the EDSS); MRI-based measures and OCT. Immunological evaluation as exploratory analysis",
            "SecondaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nInflammatory forms of MS\n\nRelapsing-remitting MS (RRMS) patients\nSecondary progressive MS (SPMS) patients with continued relapses\nPrimary progressive MS (PPMS) patients with enhancing MRI lesions and positive CSF (oligoclonal banding)\nAge 18-50 years\nDisease duration >= 2 and >= 10 years\nEDSS 3.0 - 6.5\n\nProgression, continued relapses or worsening MRI after at least a year of attempted therapy evidenced by:\n\nIncrease of >= 1 EDSS point (if baseline EDSS <= 5.0) or 0.5 EDSS points (if baseline EDSS >= 5.5), or quantifiable, objective evidence of equivalent progression\n>= 1 moderate-severe relapses in past 18 months\n>= 1 Gadolinium enhancing lesions (double or triple dose Gadolinium)\n>= 1 new T2 lesion\nFor PPMS only, >= 1 Gadolinium enhancing lesions\nHas given informed consent to participate in the study.\n\nExclusion Criteria:\n\nSPMS without ongoing relapses\nPPMS without positive CSF or Gadolinium enhancing lesions\n<= 3 months since treatment with any immunosuppressive therapy\n<=1 month since last treatment with interferon-B or glatiramer acetate\nCorticosteroid treatment <= 30 days\nRelapse <= 60 days\nHistory of cancer or clinical or laboratory results indicative of severe systemic diseases, including infection for HIV, Hepatitis B or C\nAny metallic or electronic device that precludes from undergoing MRI\nPregnancy or lactation\nCurrent treatment with an investigational therapy",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "50 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Albert Saiz, MD",
            "OverallOfficialAffiliation": "Hospital Clinic of Barcelona",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Neurology Service, Hospital Clinic de barcelona",
            "LocationCity": "Barcelona",
            "LocationZip": "08036",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "25436769",
            "ReferenceType": "derived",
            "ReferenceCitation": "Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936. eCollection 2014."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009103",
            "ConditionMeshTerm": "Multiple Sclerosis"
          },
          {
            "ConditionMeshId": "D000012598",
            "ConditionMeshTerm": "Sclerosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000020278",
            "ConditionAncestorTerm": "Demyelinating Autoimmune Diseases, CNS"
          },
          {
            "ConditionAncestorId": "D000020274",
            "ConditionAncestorTerm": "Autoimmune Diseases of the Nervous System"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000003711",
            "ConditionAncestorTerm": "Demyelinating Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11212",
            "ConditionBrowseLeafName": "Multiple Sclerosis",
            "ConditionBrowseLeafAsFound": "Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14567",
            "ConditionBrowseLeafName": "Sclerosis",
            "ConditionBrowseLeafAsFound": "Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21251",
            "ConditionBrowseLeafName": "Demyelinating Autoimmune Diseases, CNS",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21247",
            "ConditionBrowseLeafName": "Autoimmune Diseases of the Nervous System",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6061",
            "ConditionBrowseLeafName": "Demyelinating Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}